Exelixis Inc
EXEL
70.10−0.60 (−0.85%)Nov 12, 6:05 PM ET
Key stats
- Open
- 70.70
- Day high
- 70.95
- Day low
- 69.67
- Previous close
- 70.70
- Volume
- 1.63M
- VWAP
- 70.08
- 52-week high
- 73.69
- 52-week low
- 39.71
- Market cap
- 17.25B
- Shares out
- 244.01M
- Employees
- 1,077
- Listed
- 2000
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · ALAMEDA, CA · exelixis.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 6.6K
- Put open interest
- 2.6K
- Put/call
- 0.39
- At-the-money IV
- 39.2%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 57.50 put | 0.75 | Oct 29, 3:44 PM | 1.5K | 1.5K | 102.1% |
| 65 call | 5.90 | Nov 10, 1:34 PM | 52 | 2.3K | 47.9% |
| 70 call | 1.65 | Nov 12, 1:15 PM | 27 | 1.4K | 39.2% |
| 80 call | 0.25 | Nov 10, 10:36 AM | 25 | 138 | 65.4% |
| 67.50 call | 3.09 | Nov 12, 3:46 PM | 23 | 565 | 46.9% |
| 65 put | 0.25 | Nov 11, 12:05 PM | 15 | 103 | 37.4% |
Quarterly results
Massive · Oct 29, 2026| Q3 2026 to Oct 2, 2026 | Q2 2026 to Jul 3, 2026 | Q1 2026 to Apr 3, 2026 | Q4 2025 to Jan 2, 2026 | |
|---|---|---|---|---|
| Revenue | $658.70M | $628.69M | $610.81M | $598.66M |
| Gross profit | $632.46M | $608.03M | $590.86M | $572.18M |
| Operating income | $268.42M | $248.41M | $251.34M | $235.22M |
| Net income | $218.09M | $212.05M | $210.47M | $244.53M |
| Diluted EPS | 0.85 | 0.82 | 0.79 | 0.88 |
| Operating cash flow | $279.96M | $307.74M | $251.84M | $333.51M |
| Assets | $2.51B | $2.49B | $2.59B | $2.84B |
| Liabilities | $679.66M | $650.47M | $657.85M | $683.10M |
| Equity | $1.83B | $1.84B | $1.94B | $2.16B |
Technicals
Massive · Nov 12, 2026- 50-day average62.09
- 200-day average52.11
- RSI (14 days)62.2
Short interest
Massive · Oct 30, 2026- Oct 30, 202625.59M shares · 11.7 days to cover
- Oct 15, 202627.31M shares · 11.3 days to cover
- Sep 30, 202628.18M shares · 12.7 days to cover
- Sep 15, 202626.40M shares · 12.4 days to cover
News coverage
No stories about Exelixis Inc right now.